Zhitong Financial App News, Conn Bay (600572.SH) announced that recently, the company submitted a new drug marketing application (NNDA) to the US Food and Drug Administration (FDA) through the introduction of a licensed (license-in) cooperative product, Adneuris Therapeutics, Inc. (“Adneuris” for short, a wholly-owned subsidiary of Tris Pharma, Inc.) to the US Food and Drug Administration (FDA) to treat adults severe acute pain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.